SUNNYVALE, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, today announced the pricing of an upsized secondary public offering of 4,200,000 shares of its common stock by certain selling stockholders at a public offering price of $39.50 per share. In addition, certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 630,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. Silk Road Medical will not receive any proceeds from the sale of shares of common stock by the selling stockholders. The offering is expected to close on August 13, 2019, subject to the satisfaction of customary closing conditions.
J.P. Morgan Securities LLC and BofA Merrill Lynch are acting as joint book-running managers for the offering. BMO Capital Markets and Stifel are acting as co-managers for the offering.
Read More: https://www.globenewswire.com/news-release/2019/08/08/1899718/0/en/Silk-Road-Medical-Announces-Pricing-of-Upsized-Public-Offering.html
SUNNYVALE, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”), a company focused on reducing the risk of stroke and its devastating impact, announced today the commencement of a proposed underwritten public offering of 3,500,000 shares of its common stock by certain selling stockholders. In addition, certain selling stockholders expect to grant the underwriters a 30-day option to purchase an additional 525,000 shares of its common stock in the offering. Silk Road Medical will not receive any of the proceeds from the sale of the shares of its common stock being offered by the selling stockholders. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Via: PR Newswire
Digital Care Leader's Integrated Program Supports Individuals Dealing with Chronic Disease, Mental Health Issues
Via: PR Newswire
-- Singular Bio's Technology Designed to Enable High-Quality, Low-Cost Genetic Testing at Scale to Expand Access to Non-Invasive Prenatal Screening --
Vikram S Kashyap, co-principal investigator of the ROADSTER 2 trial, today presented the final 30-day outcomes of the post-market approval study in a late-breaking trial session at the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM; 12–15 June, National Harbor, USA). The data show the sustained safety and efficacy of transcarotid artery revascularisation (TCAR) with Silk Road Medical’s Enroute system. In this interview, Kashyap speaks to Vascular News about the procedure, and how TCAR trialists are hoping to make an impact for patients needing carotid revascularisation.
Final Results Presented in Late-Breaking Session at Society for Vascular Surgery 2019 Vascular Annual Meeting
NATIONAL HARBOR, Md., June 13, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM). In a headline presentation, Dr. Mahmoud Malas of the University of California, San Diego School of Medicine shared updated results for the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project.
Silk Road Medical Announces Key TCAR Presentations at the Society for Vascular Surgery 2019 Vascular Annual Meeting
SUNNYVALE, Calif. – June 4, 2019 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced key data from the SVS TCAR Surveillance Project and ROADSTER-2 study will be presented at the upcoming Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM), June 12-15 at the Gaylord National Resort & Convention Center in National Harbor, Maryland.
For diabetic workers, access to a refrigerator and insulin breaks are not a workplace perk. They are potentially a matter of life and death.
Via: The Carle Foundation
The signs of Robert Nemeth’s mini-stroke were clear.
“I was standing in front of the refrigerator, and my right arm wouldn’t move. I realized something was very wrong,” Nemeth said.
The Sadorus man needed a procedure to help clear his carotid artery, which was 90 percent blocked. Because of previous radiation treatments to his neck, traditional surgery could have been risky.
Thankfully, surgeons at Carle Heart & Vascular Institute perform a minimally invasive procedure to reach the carotid artery through a small incision in the clavicle. Carle is the only Illinois hospital outside the Chicago and St. Louis areas to offer TransCarotid Artery Revascularization (TCAR).
“This is the future,” said Carle vascular surgeon Brian Beeman, MD. “TCAR is a much safer option for patients who are at high risk for traditional surgery, including patients with congestive heart failure and recent heart attack.”
Read More: https://newsroom.carle.org/quality-innovation/stroke-prevention-procedure-serves-as-option-for-high-risk-patients.htm